Point-of-Care Testing in PKU: A New ERA of Blood Phenylalanine Monitoring
Pinto et al.
The finding, in our words
The Egoo Phe system showed strong concordance with dried blood spot testing across 100 paired samples, with median phenylalanine 274 versus 270 μmol/L and readings a mean 4.6% higher, and high caregiver acceptance; the small sample size limits generalisability and further validation in larger cohorts is required.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Dried blood spot sampling matched venous serum performance for islet autoantibody detection and was considered minimally invasive and convenient by parents and stakeholders, supporting its use for decentralised screening in home or community settings.
VAMS microsampling found no significant difference from venous blood for tacrolimus in paediatric patients; samples were stable for 14 days, with average difference between paired at-home samples of 0.12 ± 0.94 ng/mL.
Dried VAMS and DBS samples collected at home and analysed after a median of three days showed poor agreement with standard venous or capillary blood for HbA1c monitoring. In contrast, wet VAMS samples analysed immediately demonstrated excellent agreement, indicating that sample drying and delayed analysis compromise reliability for decentralised HbA1c measurement.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.